

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|----------------------|
| Application Number | 10/602,447 |
| Filing Date | June 24, 2003 |
| First Named Inventor | Erik Ho Fong Wong |
| Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 00054.US1 (PC24974A) |

Sheet 1 of 3

U. S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| RC | | US- 2831027 | 04-15-1958 | Karl Pfister III, et al. | |
| RC | | US- 4788189 | 11-29-1988 | Howard I. Glazer | |
| RC | | US- 5316759 | 05-31-1994 | Jed E. Rose, et al. | |
| RC | | US- 5574052 | 11-12-1996 | Jed E. Rose, et al. | |
| RC | | US- 6004970 | 12-21-1999 | Stephanie O'Malley, et al. | |
| RC | | US- 6197827 | 03-06-2001 | Douglas D. Cary | |
| RC | | US- 6262049 | 07-17-2001 | Vicki L. Coffin, et al. | |
| RC | | US- 6352986 | 03-05-2002 | Fred Hassan, et al. | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| RC | | WO 94/28888 | 12-22-1994 | Manuel F. Balandrin, et al | | |
| RC | | WO 99/52531 | 10-21-1999 | Fred Hassan, et al. | | |
| RC | | WO 99/58130 | 11-18-1999 | Duncan P. Taylor, et al. | | |
| RC | | DE 10004547 | 08-09-2001 | Rainer K. Liedtke | | |
| | | | | | | |
| | | | | | | |

| | | | |
|-----------------------|-----------------|--------------------|------------|
| Examiner Signature | /Renee Claytor/ | Date Considered | 11/21/2006 |
|-----------------------|-----------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

USPN 10/602,447 Filed June 24, 2003
Docket No. 00054.US1 (PC24974A)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|-------------------|------------------------|----------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/602,447 | | |
| | | Filing Date | June 24, 2003 | | |
| | | First Named Inventor | Erik Ho Fong Wong | | |
| | | Art Unit | | | |
| Examiner Name | | | | | |
| Sheet | 2 | of | 3 | Attorney Docket Number | 00054.US1 (PC24974A) |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|----------------|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| RC | + | F. BENAZZI, et al., "Urinary Retention With Reboxetine-Fluoxetine Combination in a Young Man", Canadian Journal of Psychiatry, December 2000, pp 936, Vol. 45, No. 10 | | |
| RC | + | A. R. CAGGIULA, et al., "Different Methods of Assessing Nicotine-Induced Antinociception May engage Different Neural Mechanisms", Psychopharmacology, 1995, pp 301-306, Vol. 122 | | |
| RC | + | M. W. DECKER, et al., "Erysodine, a Competitive Antagonist at Neuronal Nicotinic Aetylcholine Receptors", European Journal of Pharmacology, 1995, pp 79-89, Vol 280 | | |
| RC | + | J. N. DIANA, et al., "Nicotine-induced Skeletal Muscle Vasodilation is Mediated by Release of Epinephrine from Nerve Terminals", American Journal of Physiology, 1990, pp H1718-H1729, Vol. 259 | | |
| RC | + | B. E. GARRETT, et al., "Tobacco Addiction and Pharmacological Interventions", Expert Opinion of Pharmacotherapy, 2001, pp 1545-155, Vol. 2, No. 10 | | |
| RC | + | T. HISAYAMA, et al., "Mechanism of Action of Nicotine in Isolated Urinary Bladder of Guinea-pig", British Journal of Pharmacology, 1988, pp 465-472, Vol. 95 | | |
| RC | + | J. R. HUGHES, et al., "Anxiolytics for Smoking Cessation", 2002, Issue 1, Cochran Database of Systematic Reviews | | |
| RC | + | C. L. NUNN-THOMPSON, et al., "Pharmacotherapy for Smoking Cessation", Clinical Pharmacy, October 1998, pp 710-720, Vol. 8 | | |
| RC | + | K. S. OKUYEMI, et al., "Pharmacotherapy of Smking Cessation", Arch Fam Med, March 2000, pp 270-281, Vol. 9 | | |
| RC | + | C. RAPIER, et al., "Nicotinic Modulation of [3H] Dopamine Release from Striatal Synaptosomes: Pharmacological Characterisation", Journal of Neurochemistry, 1990, pp 937-945, Vol. 54, No. 3 | | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Renee Claytor/ | Date Considered | 11/21/2006 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|----------------------|
| Application Number | 10/602,447 |
| Filing Date | June 24, 2003 |
| First Named Inventor | Erik Ho Fong Wong |
| Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 00054.US1 (PC24974A) |

Sheet

3

of

3

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| RC | + | I. P. STOLERMAN, et al., " Selective Antagonism of Behavioural Effects of Nicotine by Dihydro-Beta-Erythroidine in Rats", Psychopharmacology, 1997, pp 390-397, Vol. 129 | |
| RC | + | F. S. TENNANT, et al., "Withdrawal From Nicotine Dependence Using Mecamylamine: Comparison of Three-Week and Six-Week Dosage Schedules", NIDA Research Monograph, 1984, pp 291-297, Vol. 55 | |
| RC | + | V. E. WOTRING, et al., " The Inhibitory Effects of Nicotinic Antagonists on Currents Elicited by Gaba in Rat Hippocampal Neurons", Neuroscience, 1995, pp 293-300, Vol. 67, No. 2 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |


| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Renee Claytor/ | Date Considered | 11/21/2006 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



| | | | | | | | | | | | | | | |
|--|---|-----------------------------|--|---|---|-----------------------|---|------|-----------|-----------|----------------|-------------|----------|----------------------------------|
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | ATTY. DOCKET NO. 24974A | | | | SERIAL NO. 10/602,447 | | | | | | | | |
| | | APPLICANT Erik Fo Hong Wong | | | | | | | | | | | | |
| | | FILING DATE June 24, 2003 | | | | GROUP 1614 | | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| RC | 0 | 2 | 0 | 0 | 1 | 3 | 3 | 1 | 2 | 31-Jan-02 | J. Schildkraut | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| DOCUMENT NUMBER | | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | | |
| | | | | | | | | | | | | YES | NO | |
| RC | 0 | 0 | 0 | 5 | 9 | 4 | 8 | 6 | 12-Oct-00 | WO | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| RC | | | Harkin A. <i>et al.</i> , "Activity and onset of action of reboxetine and effects of combination of sertraline in an animal model of depression", <i>Europ. J. of Pharmacology</i> , Vol. 365, 1999, pps. 123-132 | | | | | | | | | | | |
| RC | | | Harkin A. <i>et al.</i> , "Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and β 1-adrenergic receptors in an animal model of depression", <i>J. Neural Transmission</i> , Vol 107, 2000, pps. 1213-1227 | | | | | | | | | | | |
| RC | | | Ferri M. <i>et al.</i> , "Sertraline and reboxetine association in depressive pseudodementia: good cardiovascular effects", <i>Arch. Gerontol. Geriatrics</i> , Suppl. 7 2001 pps 121-125 | | | | | | | | | | | |
| RC | | | Demitrack, M.A., "Can Monoamine-Based Therapies Be Improved?", <i>J. Clinical Psychiatry</i> Vol. 63, 2002 | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| EXAMINER /Renee Claytor/ DATE CONSIDERED 11/21/2006 | | | | | | | | | | | | | | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | | |

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE